Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Haemophilia B Clear all
No Longer Available No phase listed Expanded access

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

NCT01968655
View directory record Official record
Conditions
Acquired Hemophilia A
Interventions
OBI-1
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Not applicable Interventional

The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs

NCT00212459
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Counseling, Control
Behavioral
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
12 Years to 20 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Jul 21, 2026, 5:03 AM EDT
Active, not recruiting Phase 2 Interventional

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

NCT03307980
View directory record Official record
Conditions
Hemophilia B
Interventions
PF-06838435 (formerly SPK-9001)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
17
States / cities
Sacramento, California • Metairie, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Withdrawn Phase 3 Interventional

Study of a Gene Therapy Treatment for Hemophilia A

NCT06297486
View directory record Official record
Conditions
Hemophilia A
Interventions
SPK-8011
Genetic
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
27
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 21, 2026, 5:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

NCT04082429
View directory record Official record
Conditions
Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

NCT02618915
View directory record Official record
Conditions
Hemophilia B
Interventions
DTX101
Genetic
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

NCT00768287
View directory record Official record
Conditions
Hemophilia B
Interventions
IB1001, nonacog alfa
Biological
Lead sponsor
Medexus Pharma, Inc.
Industry
Eligibility
5 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

NCT03587116
View directory record Official record
Conditions
Hemophilia B, Hemophilia A
Interventions
Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 21, 2026, 5:03 AM EDT
Completed No phase listed Observational

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

NCT02190149
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant])
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
13 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Phase I/IIa Study of FIXFc in Hemophilia B Patients

NCT00716716
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 5:03 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

NCT00076557
View directory record Official record
Conditions
Hemophilia B
Interventions
Adeno-Associated Viral with Human Factor IX
Genetic
Lead sponsor
Avigen
Industry
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2007 · Synced Jul 21, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

NCT05789537
View directory record Official record
Conditions
Hemophilia B with Inhibitor, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 21, 2026, 5:03 AM EDT
Completed No phase listed Observational

Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia

NCT01988532
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

NCT02448680
View directory record Official record
Conditions
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions
Coagulation FVIIa (Recombinant)
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

NCT01561924
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
16 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Berkeley, California • Los Angeles, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

NCT02035605
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

NCT02234310
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
11
States / cities
Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 21, 2026, 5:03 AM EDT
Terminated No phase listed Observational

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

NCT02392156
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
rFVIIIFc, rFIXFc, non-Fc FVIII replacement products, non-Fc FIX replacement products
Biological · Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Los Angeles, California • East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

PF-06741086 Long-term Treatment in Severe Hemophilia

NCT03363321
View directory record Official record
Conditions
Hemophilia A or B
Interventions
PF-06741086
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

NCT03938792
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 21, 2026, 5:03 AM EDT
Completed No phase listed Observational

Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B

NCT00195221
View directory record Official record
Conditions
Hemophilia B, Allergic Reactions
Interventions
Not listed
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Not listed
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Study Evaluating rFIX; BeneFIX® in Hemophilia B

NCT00093171
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIX
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2009 · Synced Jul 21, 2026, 5:03 AM EDT
Withdrawn Phase 4 Interventional

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

NCT00168051
View directory record Official record
Conditions
Hemophilia A
Interventions
ReFacto, Advante
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

NCT02020369
View directory record Official record
Conditions
Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions
Coagulation Factor VIIa (Recombinant)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
12 Years to 75 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 21, 2026, 5:03 AM EDT